Micardis®
Sponsors
Boehringer Ingelheim
Conditions
Hypertension
Unknown Phase
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension
CompletedNCT02176850
Start: 1999-01-31Updated: 2014-07-08
Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension
CompletedNCT02202525
Start: 2001-01-31Updated: 2014-07-29
Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure
CompletedNCT02242864
Start: 2006-01-31Updated: 2014-09-17
Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure
CompletedNCT02242331
Start: 2001-06-30Updated: 2014-09-17
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus
CompletedNCT02242825
Start: 2006-01-31Updated: 2014-09-17
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension
CompletedNCT02242357
Start: 2003-01-31Updated: 2014-09-17
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)
CompletedNCT02262611
Start: 2003-01-31Updated: 2014-10-13
Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)
CompletedNCT02262637
Start: 2003-09-30Updated: 2014-10-13